PHACTR1 Activators are a collection of chemical compounds that indirectly promote the functional activity of PHACTR1, primarily through the modulation of cyclic AMP (cAMP) levels and subsequent activation of protein kinase A (PKA). Forskolin, Rolipram, IBMX, and Epinephrine all function to elevate intracellular cAMP directly or through inhibition of its degradation, thereby enhancing PKA signaling. Activated PKA is known to phosphorylate various substrates, and this post-translational modification can lead to the activation of PHACTR1, which plays a pivotal rolein actin filament organization and modulation of cellular signaling. The phosphorylation of PHACTR1 by PKA may influence its ability to interact with actin and other binding partners within the cell, augmenting its regulatory functions. Similarly, Isoproterenol, a synthetic catecholamine, and 8-Br-cAMP, a cAMP analog, activate PKA, potentially leading to enhanced PHACTR1 activity. Vinpocetine, Cilostamide, Milrinone, Anagrelide, and Zardaverine all inhibit various phosphodiesterases, leading to increased cAMP levels and activation of PKA. This cascade of events may culminate in the phosphorylation and activation of PHACTR1, influencing its role in cellular signaling and actin dynamics.
Sildenafil, although primarily known as a PDE5 inhibitor which increases cGMP levels, can also affect the cAMP signaling pathways. This influence may indirectly lead to the activation of PHACTR1 through enhanced PKA activity. The interplay of cGMP and cAMP signaling is intricate, but the enhancement of PKA activity by Sildenafil could potentially lead to the phosphorylation of PHACTR1, thus promoting its functional activity within the cell. Collectively, these PHACTR1 Activators utilize the common mechanism of cAMP-PKA pathway modulation to exert their effects, yet each does so through a distinct pharmacological action. This specificity provides a multi-faceted approach to indirectly activating PHACTR1, emphasizing the importance of PKA-mediated phosphorylation in PHACTR1 functionality.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased levels of cyclic AMP (cAMP) in cells. Elevated cAMP activates PKA (protein kinase A), which can phosphorylate and thereby regulate various proteins, including PHACTR1, potentially enhancing its function in actin filament organization and cellular signaling. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase-4 (PDE4), an enzyme that degrades cAMP. Inhibition of PDE4 by Rolipram results in increased cAMP levels, similar to Forskolin, thus indirectly promoting PHACTR1 activation through the same PKA-mediated phosphorylation mechanisms. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX, or 3-Isobutyl-1-methylxanthine, is a non-selective inhibitor of phosphodiesterases, which increases intracellular cAMP levels. The result is enhanced PKA activity, which can indirectly lead to the activation of PHACTR1 through phosphorylation. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to adrenergic receptors, which can lead to the activation of adenylate cyclase and an increase in cAMP levels. The subsequent activation of PKA could enhance PHACTR1 activity through phosphorylation that affects its role in the regulation of actin polymerization. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a synthetic catecholamine that stimulates beta-adrenergic receptors, causing an increase in intracellular cAMP and activation of PKA. This, in turn, may lead to the phosphorylation and activation of PHACTR1. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP) is a cAMP analog that activates PKA. It serves as a more stable compound that can enhance phosphorylation events, potentially leading to the activation of PHACTR1. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a PDE1 inhibitor that can thereby increase cAMP and cGMP levels. This elevation may indirectly activate PKA and result in the phosphorylation and activation of PHACTR1. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide specifically inhibits PDE3, which contributes to elevated cAMP levels in cells, potentially leading to PKA activation and subsequent phosphorylation of PHACTR1, enhancing its activity in cellular signaling pathways. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone is a selective PDE3 inhibitor that increases cAMP levels. This increase is anticipated to activate PKA, potentially leading to the phosphorylation and functional enhancement of PHACTR1. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide is also a PDE3 inhibitor with similar effects to Cilostamide and Milrinone, raising cAMP levels, activating PKA, and potentially enhancing the activity of PHACTR1 via phosphorylation. | ||||||